Prostate Cancer Drugs Market 2021-2026 Forecast and COVID-19 Impact on Business, Industry, Revenue and Actionable Insights
The Global Prostate Cancer
Drugs Market report provides information by Key Players, Geography, End users,
Applications, Competitor analysis, Sales, Revenue, Price, Gross Margin, Market
Share, Import-Export, Trends and Forecast.
The report introduces Prostate Cancer Drugs
basic information including definition, classification, application, industry
chain structure, industry overview, policy analysis, and news analysis.
Insightful predictions for the Prostate Cancer Drugs market for the coming few
years have also been included in the report.
Development policies and plans are discussed as
well as manufacturing processes and cost structures are also analyzed. This
report also states import/export consumption, supply and demand. Cost, price,
revenue and gross margins.
Know more https://www.insidemarketreports.com/report/9/791909/Prostate-Cancer-Drugs
Key players in this market are Prostate Cancer Drugs
Market
AbbVie
Novartis
Johnson & Johnson
Astellas Pharma
Merck Group
Astra Zeneca
Bayer HealthCare
GlaxoSmithKline
Sanofi
Amgen
Takeda Pharmaceuticals
Get sample report https://www.insidemarketreports.com/sample-request/9/791909/prostate-cancer-drugs-markets
By
Type
Hormonal Therapy
Chemotherapy
Immunotherapy
Targeted Therapy
By Application
Clinics
Hospitals
Other
Recent
Development Of Prostate Cancer Drugs Market
In June 2021, Novartis' 177Lu-PSMA-617 has been granted as a
breakthrough therapy by the US Food and Drug Administration (FDA) for the treatment
of metastatic castration-resistant prostate cancer (mCRPC). 177Lu-PSMA-617 is
an investigational radioligand therapy that combines a targeting compound and a
therapeutic radioisotope. In January 2021, Myovant has partnered with Pfizer to
commercialise Orgovyx (relugolix), a prostate cancer drug that will be approved
in December 2020. In June 2020, In the United States, Dr. Reddy introduced
generic Abiraterone Acetate Tablets USP, 250 mg, a therapeutic equivalent
generic version of Zytiga (abiraterone acetate) for prostate cancer.
Comments
Post a Comment